Seminars in Radiation Oncology
Volume 17, Issue 3 , Pages 206-222 , July 2007

Radiotherapy of Hodgkin Lymphoma: Indications, New Fields, and Techniques

  • Theodore Girinsky, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Theodore Girinsky, MD, Department of Radiation Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France.
    • ,
  • Mithra Ghalibafian, MD

References 

  1. Aleman BMP, van den Belt-Dusebout AW, Klokman WJ. Long-term cause-specific mortality of patients treated for Hodgkin disease. J Clin Oncol. 2003;21:3431–3439
  2. Bhatia S, Robison LL, Oberlin O. Breast cancer and other second neoplasms after childhood Hodgkin disease. N Engl J Med. 1996;334:745–751
  3. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin disease. JAMA. 1993;270:1949–1955
  4. Koontz F, Kirkpatrick P, Clough W. Combined modality therapy versus radiotherapy alone for treatment of early stage Hodgkin disease: Cure versus complications. J Clin Oncol. 2005;24:605–611
  5. Mauch P. Second malignancies after curative radiation therapy for good prognosis cancers. Int J Radiat Oncol Biol Phy. 1995;33:959–960
  6. Ng AK, Bernardo MP, Weller E. Long-term survival and competing causes of death in patients with early-stage Hodgkin disease treated at age 50 or younger. J Clin Oncol. 2002;20:2101–2108
  7. van Leeuwen FE, Klokman WJ, Stovall M. Role of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin’s disease. J Natl Cancer Inst. 2003;95:971–980
  8. Longo DL. Radiation therapy in the treatment of Hodgkin disease—Do you see what I see?. J Natl Cancer Inst. 2003;95:928–929
  9. Klimm B, Diehl V, Pfistner B. Current strategies of the German Hodgkin Study Group (GHSG). Eur J Haematol. 2005;75(suppl 66):125–134
  10. Ferme C, Eghbali H, Hagenbeek A. MOPP/ABV (M/A) hybrid and irradiation in unfavourable supradiaphragmatic clinical stages I-II Hodgkin disease: comparison of three treatment modalities (Preliminary results of the EORTC-GELA H8-U randomised trial in 995 patients). Blood. 2000;96:576;(abstr 2473)
  11. Noordijk EM, Thomas J, Ferme C. First results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable and unfavourable early stage Hodgkin lymphoma. Proc Am Soc Clin Oncol. 2005;124:abstr 6505
  12. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease (International Prognostic Factors Project on Advanced Hodgkin disease). N Engl J Med. 1998;339:1506–1514
  13. Noordijk EM, Carde P, Dupouy N. Combined-modality therapy for clinical stage I or II Hodgkin lymphoma: Long-term results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials. J Clin Oncol. 2006;24:3128–3135
  14. Press OW, LeBlanc M, Lichter AS. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin disease. J Clin Oncol. 2001;19:4238–4244
  15. Sieber M, Franklin J, Tesch H. Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin’ s disease: Results of the German Hodgkin lymphoma Study Group (GHSG) trial HD7. Blood. 2002;100:93;(abstr 341)
  16. Hagenbeek A, Eghbali H, Ferme C. Three cycles of MOPP/ABV (M/A) hybrid and involved-field irradiation is more effective than subtotal nodal irradiation (STNI) in favorable supradiaphragmatic clinical stage (CS) I-II Hodgkin disease (HD): Preliminary results of the EORTC-GELA trial in 543 patients. Blood. 2000;96:575;(abstr 2472)
  17. Bonadonna G, Bonfante V, Viviani S. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin disease: Long-term results. J Clin Oncol. 2004;22:2835–2841
  18. Eich H, Mueller R, Engert A. Comparison of 30 Gy versus 20 Gy involved field radiotherapy after two versus four cycles of ABVD in early stage Hodgkin lymphoma: Interim analysis of the German Hodgkin Study Group Trial HD10. Int J Radiat Oncol Biol Phys. 2005;63:1–2(abstr)
  19. Diehl V, Brillant C, Engert A. Investigating reduction of combined-modality treatment intensity in early stage Hodgkin lymphoma (Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSD)). Proc Am Soc Clin Oncol. 2005;124:6506;(abstr)
  20. Horning SJ, Hoppe RT, Advani R. Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin disease: Mature data in early and advanced stage patients. Blood. 2004;104:(abstr 308)
  21. Engert A, Schiller P, Josting A. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavourable Hodgkin lymphoma: Results of the HD8 trial of the German Hodgkin Lymphoma Study Group. J Clin Oncol. 2003;21:3601–3608
  22. Klimm BC, Engert A, Brillant C. Comparison of BEACOPP and ABVD chemotherapy in intermediate stage Hodgkin lymphoma: Results of the fourth interim analysis of the HD-11 trial of the GHSG. Proc Am Soc Clin Oncol. 2005;124:(abstr 6507)
  23. Diehl V, Loeffler M, Pfreundschuh M. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin disease. Ann Oncol. 1995;6:901–910
  24. Laskar S, Gupta T, Vimal S. Consolidation radiation after complete remission in Hodgkin disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need?. J Clin Oncol. 2004;22:62–68
  25. Yahalom J, Ryu J, Straus DJ. Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin disease treated with alternating chemotherapy combinations. J Clin Oncol. 1991;9:2193–2201
  26. Fabian CJ, Mansfield CM, Dahlberg S. Low-dose involved field radiation after chemotherapy in advanced hodgkin disease (A Southwest Oncology Group Randomized study). Ann Intern Med. 1994;120:903–912
  27. Ferme C, Mounier N, Casasnovas O. Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: A study by the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood. 2006;107:4636–4642
  28. Brice P, Colin P, Berger F. Advanced Hodgkin disease with large mediastinal involvement can be treated with eight cycles of chemotherapy alone after a major response to six cycles of chemotherapy. Cancer. 2001;92:453–459
  29. Aleman BMP, Raemaekers JMM, Tirelli U. Involved-field radiotherapy for advanced Hodgkin lymphoma. N Engl J Med. 2003;348:2396–2406
  30. Loeffler M, Brosteanu O, Hasenclever D. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin disease. J Clin Oncol. 1998;16:818–829
  31. Duggan DB, Petroni GR, Johnson JL. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin disease: Report of an Intergroup Trial. J Clin Oncol. 2003;21:607–614
  32. Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin disease trial. N Engl J Med. 2002;346:1417–1418
  33. Horning SJ, Hoppe RT, Breslin S, et al. Radiotherapy for locally extensive and advanced Hodgkin disease: Mature results of a prospective clinical trial. J Clin Oncol. 2002;2:630–637
  34. Fabian C, Dahlberg T, Miller S. Efficacy of low dose involved field (LDIF) XRT in producing and maintening CR following PR induction with MOP-BAP chemotherapy in Hodgkin disease: Results of the Southwest Oncology Group Study 7808. Proc Am Soc Clin Oncol. 1989;8:253;(abstr)
  35. Aleman BMP, Raemakers JMM, Tomsic R. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2007;67:19–30
  36. Martens C, Hodgson DC, Wells WA. Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2006;64:1183–1187
  37. Girinsky T, Lapusan S, Ribrag V. Phase II study of concomitant chemoradiotherapy in bulky refractory or chemoresistant relapsed lymphomas. Int J Radiat Oncol Biol Phys. 2005;61:476–479
  38. Yahalom J, Gulati SC, Toia M. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy and autologous bone marrow transplantation for refractory and relapsing patients with Hodkgin’s disease. J Clin Oncol. 1993;11:1062–1070
  39. Poen JC, Hoppe RT, Horning SJ. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin disease: The impact of involved field radiotherapy on patterns of failure and survival. Int J Radiat Oncol Biol Phys. 2005;61:476–479
  40. Travis LB, Hill D, Dores GM. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst. 2005;97:1428–1436
  41. Salloum E, Doria R, Schubert W. Second solid tumors in patients with Hodgkin disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol. 1996;14:2435–2443
  42. Longo DL. Radiation therapy in Hodgkin disease: Why risk a Pyrrhic victory?. J Natl Cancer Inst. 2005;97:1394–1395
  43. Londo DL. Hodgkin disease: The sword of Damocles resheathed. Blood. 2004;104:3418
  44. Franklin JG, Paus MD, Pluetschow A: Chemotherapy, radiotherapy and combined modality for Hodgkin disease with emphasis on second cancer risk. The Cochrane Collaboration. Cochrane Library, Eds Wiley, issue 2, 2006
  45. Straus DJ, Portlock CS, Qin J. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004;104:3483–3489
  46. Pavlovsky S, Maschio M, Santarelli MT. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin disease. J Natl Cancer Inst. 1988;80:1466–1473
  47. Meyer RM, Gospodarowicz MK, Connors JM. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:4634–4642
  48. Shahidi M, Kamangari N, Ashley S. Site of relapse after chemotherapy alone for stage I and II Hodgkin disease. Radiother Oncol. 2006;78:1–5
  49. Nachman JB, Sposto R, Herzog P. Randomized comparison of low-dose involved- field radiotherapy and no radiotherapy for children with Hodgkin disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20:3765–3771
  50. Martin WG, Ristow KM, Habermann TM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin lymphoma. J Clin Oncol. 2005;23:7614–7620
  51. Doyle JJ, Neugut AI, Jacobson JS. Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol. 2005;23:8597–8605
  52. Aviles A, Neri N, Nambo JM. Late cardiac toxicity secondary to treatment in Hodgkin disease (A study comparing doxorubicin, epirubicin, and mitoxantrone in combined therapy). Leuk Lymphoma. 2005;46:1023–1028
  53. Moser EC, Noordijk EM, van Leeuwen FE. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood. 2006;107:2912–2919
  54. Donaldson SS, Hudson MM, Lamborn KR. VAMP and low dose, involved- field radiation for children and adolescents with favorable, early-stage Hodgkin disease: Results of a prospective clinical trial. J Clin Oncol. 2002;20:3081–3087
  55. Landman-Parker J, Pacquement H, Leblanc T. Localized childhood Hodgkin disease: Response-adapted chemotherapy with etoposide, bleomycin, vinblastine and prednisone before low-dose radiation therapy (Results of the French Society of Pediatric Oncology Study MDH90). J Clin Oncol. 2000;18:1500–1507
  56. van Leeuwen FE, Klokman WJ, van’t Veer MB. Long-term risk of second malignancy in survivors of Hodgkin disease treated during adolescence or young adulthood. J Clin Oncol. 2000;18:487–497
  57. Andre M, Mounier N, Leleu X. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: A GELA cohort study on 2837 patients. Blood. 2004;103:1222–1228
  58. Yahalom J. Don’t throw out the baby with the bathwater: On optimizing cure and reducing toxicity in Hodgkin lymphoma. J Clin Oncol. 2006;24:544–548
  59. Carde P, Koscielny S, Franklin J. Early response to chemotherapy: A surrogate for final outcome of Hodkgin’s disease patients that should influence initial treatment length and intensity ?. Annals Oncol. 2002;13(suppl 1):89–91
  60. Kung FH, Schwartz CL, Ferree CR. POG 8625: A randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stage I, IIA, IIIA1, Hodgkin disease: A report from the Children’s Oncology Group. J Pediatr Hematol Oncol. 2006;28:362–368
  61. Rühl U, Albrecht M, Dieckmann K. Response-adapted radiotherapy in the treatment of pediatric Hodgkin disease: An interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys. 2001;51:1209–1218
  62. Weiner MA, Leventhal B, Brecher ML. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal irradiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin disease in Pediatric patients: A Pediatric Oncology Group Study. J Clin Oncol. 1997;15:2769–2779
  63. Kuentz M, Reyes F, Brun B. Early response to chemotherapy as a prognostic factor in Hodgkin disease. Cancer. 1983;52:780–785
  64. Hutchings M, Loft A, Hansen M. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52–59
  65. Gallamini A, Rigacci L, Merli F. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin disease. Haematologica. 2006;91:475–481
  66. Jerusalem G, Beguin Y. The place of positron emission tomography imaging in the management of patients with malignant lymphoma. Haematologica. 2005;91:442–444
  67. Mudie NY, Swerdlow AJ, Higgins CD. Risk of second malignancy after non-Hodgkin lymphoma: A British Cohort Study. J Clin Oncol. 2006;24:1568–1574
  68. Chronowski GM, Wilder RB, Tucker SL. Analysis of in-field control and late toxicity for adults with early-stage Hodgkin disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys. 2003;55:36–43
  69. Specht L, Gray RG, Clarke MJ. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin disease: A meta- analysis of 23 randomized trials involving 3 888 patients. J Clin Oncol. 1998;16:830–843
  70. Yahalom J, Mauch P. The involved field is back: Issues in delineating the radiation field in Hodgkin disease. Ann Oncol. 2002;13(suppl 1):79–83
  71. Girinsky T, van der Maazen R, Specht L. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines. Radiother Oncol. 2006;79:270–277
  72. ICRU: Prescribing, recording and reporting photon beam therapy. Report 50. International Commission on Radiation Units and Measurements. Washington DC, 1993
  73. Yahalom J. Transformation in the use of radiation therapy of Hodgkin lymphoma: New concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). Eur J Haematol. 2005;75(suppl 66):90–97
  74. Goodman KA, Toner S, Hunt M. Intensity modulated radiation therapy in the treatment of lymphoma involving the mediastinum. Int Radiat Oncol Biol Phys. 2005;62:192–206
  75. Girinsky T, Pichenot C, Beaudre A. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-conformal radiotherapy for mediastinal masses in patients with Hodgkin disease, and is there a role for beam orientation optimisation and dose constraints assigned to virtual volumes?. Int J Radiat Oncol Biol Phys. 2006;64:218–226
  76. Duan J, Shen S, Fiveash JB. Dosimetric and radiobiological impact of dose fractionation on respiratory motion induced IMRT delivery errors: A volumetric dose measurement study. Med Phys. 2006;33:1380–1387
  77. Fowler JF, Welsh JS, Howard SP. Loss of biological effect in prolonged fraction delivery. Int J Radiat Oncol Biol Phys. 2004;59:242–249
  78. Brincker H, Bentzen SM. A re-analysis of available dose-response and time-dose data in Hodgkin disease. Radiother Oncol. 1994;30:227–230

PII: S1053-4296(07)00018-5

doi: 10.1016/j.semradonc.2007.02.007

Seminars in Radiation Oncology
Volume 17, Issue 3 , Pages 206-222 , July 2007

Article Tools

* Image Usage & Resolution